Quarterly Period Covered: Quarter ended December 31, 2025 (Q1 of fiscal year 2026, which ends September 30, 2026) Company Overview: Medical device and surgical instruments manufacturer (SIC 3841), headquartered in Franklin Lakes, New Jersey, traded on NYSE Subsequent Event - Waters Corporation Divestiture: Filing includes disclosure of a subsequent event related to Waters Corporation, indicating…

Our analysis rates this filing BEARISH. BD faces a HIGH concern environment driven by the convergence of three major risk categories: (1) transformational corporate restructuring with the Waters separation effective Feb 2026, (2) materializing product liability exposure confirmed by actual verdict…

Concern level: HIGH (7.2/10). Key factors: Waters Corporation separation announced (Feb 9, 2026) - transformational divestiture creating material execution risk, financial uncertainty, and operational disruption during critical period; Product liability verdict materialized in Q1 FY2026 - Walker case (Covington, GA) resulted in both compensatory AND punitive damages awards (May 2025), confirming…

Notable risk changes: MAJOR: Waters Corporation Divestiture Announced - BD announced separation of Waters Corporation effective February 9, 2026, representing a transformational portfolio restructuring with significant execution risk and financial uncertainty; MAJOR: Product Liability Verdict Confirmed - Covington, Georgia Walker case resulted in actual compensatory and punitive damages awards (May 2025), confirming…

The model predicts BDX will underperform the S&P 500 by about 0.0% over 30 days (model confidence 65%). This is model analysis for research, not investment advice.